$90,407.16 ownership Payment -- Boehringer Ingelheim to Dr. Richard Brown
Oncologist Richard Brown Receives $90K Ownership Stake in Boehringer Ingelheim
This page provides a detailed analysis of a $90,407.16 ownership payment from Boehringer Ingelheim to Dr. Richard Brown. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $90,407.16 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Boehringer Ingelheim |
| Physician | Dr. Richard Brown |
| NPI Number | 1356445638 |
| Physician Specialty | Oncology |
| Location | City, CO |
| Date of Payment | 2025-10-02 |
| Related Drug/Device | Ozempic |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Boehringer Ingelheim made a $90.4K ownership payment to Richard Brown, a Oncology specialist in City, CO. The payment was associated with Ozempic. Boehringer Ingelheim reported a significant ownership interest payment of $90,407.16 to Dr. Richard Brown, an Oncologist. This payment, categorized as 'Ownership or Investment Interest', was made on October 2, 2025. The payment is associated with Boehringer Ingelheim, though Ozempic is not directly listed as the product for this specific ownership transaction.
Patient Guidance: What This Payment Means for You
If you are a healthcare professional with an ownership interest in a pharmaceutical company, ensure transparency with your patients about any potential influence on treatment recommendations. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests in pharmaceutical companies by oncologists are less common than payments for consulting or speaking, and this substantial amount warrants scrutiny for potential conflicts.
Regulatory Context: Sunshine Act Requirements
Physicians holding ownership or investment interests in entities that manufacture or supply drugs or devices they prescribe or use must disclose these interests under the Physician Payments Sunshine Act.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- boehringer-ingelheim
- oncology
- richard-brown
- cms-open-payments
- investment
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $90.4K payment for?
This was a ownership payment of $90.4K from Boehringer Ingelheim to Richard Brown, categorized as "Ownership or Investment Interest". It was associated with Ozempic. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Richard Brown accept pharmaceutical money?
Yes, Richard Brown received this $90.4K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Richard Brown's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $90.4K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Richard Brown's relationship with Boehringer Ingelheim?
The payment amount is substantial, indicating a potentially significant investment. This $90.4K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
The payment type is 'ownership or investment interest', distinct from payments for services or speaking engagements.
What should patients do after learning about this payment?
If you are a healthcare professional with an ownership interest in a pharmaceutical company, ensure transparency with your patients about any potential influence on treatment recommendations.
What else should I know about this ownership payment?
Dr. Brown's specialty is Oncology, which may align with Boehringer Ingelheim's product portfolio.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.